2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows

1.25K
306
2

2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows

Motley Fool2022-02-11

When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1.25K

Report

Comment（306）

jacksoncheng
·2022-05-02
經濟
Reply
2
Report
Aurum
·2022-02-14
Pls like and comment
Reply
1
Report
ty91
·2022-02-14
Ok
Reply
1
Report
SPOT_ON
·2022-02-14
Nothing beats the highest yield of HPHT ... 8 TO 9% YEARLY$HUTCHISON PORT HOLDINGS TRUST(NS8U.SI)$Dividend going XD this week
Reply
4
Report
小小只样
·2022-02-14
[Miser]
Reply
1
Report
Edwardtoh
·2022-02-13
Good
Reply
4
Report
Aninpooh
·2022-02-13
Ok
Reply
2
Report
Huntsilencer
·2022-02-13
Up
Reply
3
Report
tig2021
·2022-02-13
Ok
Reply
5
Report
sfleong1
·2022-02-13
Like n comment
Reply
5
Report
Singman
·2022-02-13
Like
Reply
5
Report
Jehms
·2022-02-13
Good
Reply
2
Report
Aaronboy
·2022-02-13
Like please
Reply
3
Report
DZL
·2022-02-12
Gilead Sciences, 3M, buy the dip for long term dividend gain
Reply
3
Report
ValuInvestor
·2022-02-12
Until $3M(MMM)$starts showing signs of better business execution, I don't see how it is a good buy
Reply
3
Report
tina go
·2022-02-12
Like
Reply
2
Report
tina go
·2022-02-12
K
Reply
2
Report
Jawslea
·2022-02-12
Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM)
Reply
4
Report
SSVC
·2022-02-12
K
Reply
2
Report
SPOT_ON
·2022-02-12
Us dividend stocks are.low yield and subjected to taxes....
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2210159258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-11 23:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2210159258","market":"us","top_or_hot":-1,"title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","media":"Motley Fool","content":"<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","article_id":"2210159258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","pubTimestamp":1644592522,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Both offer yields more than twice what the S&P 500 provides.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4512":"苹果概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4206":"工业集团企业","GILD":"吉利德科学","BK4534":"瑞士信贷持仓","MMM":"3M","BK4568":"美国抗疫概念","BK4139":"生物科技","BK4550":"红杉资本持仓"},"translate_title":"2只接近52周低点的高收益股息股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1,"MMM":1},"content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9063586538,"gmtCreate":1651493960715,"gmtModify":1676534915644,"author":{"id":"3585043179154199","authorId":"3585043179154199","name":"jacksoncheng","avatar":"https://static.tigerbbs.com/15cea2a12fcc802fa3161c7165a892de","vip":1,"hat":"https://static.tigerbbs.com/306aa047bc14b6942cda1aed925cf8c3","crmLevel":2,"crmLevelSwitch":0,"idStr":"3585043179154199","authorIdStr":"3585043179154199"},"htmlText":"經濟","listText":"經濟","text":"經濟","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9063586538","repostId":2210159258,"repostType":2,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9095052394,"gmtCreate":1644793780016,"gmtModify":1676533960985,"author":{"id":"3581551558648648","authorId":"3581551558648648","name":"Aurum","avatar":"https://static.tigerbbs.com/9b62b380c4f32358425ddfcfada4c880","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581551558648648","authorIdStr":"3581551558648648"},"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095052394","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095029131,"gmtCreate":1644791469071,"gmtModify":1676533960592,"author":{"id":"3579421475844844","authorId":"3579421475844844","name":"ty91","avatar":"https://static.tigerbbs.com/6d9451c5894d6ca0b4485bad0568f720","vip":1,"crmLevel":8,"crmLevelSwitch":0,"idStr":"3579421475844844","authorIdStr":"3579421475844844"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095029131","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095061733,"gmtCreate":1644789438439,"gmtModify":1676533960414,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Nothing beats the highest yield of HPHT ... 8 TO 9% YEARLY<a href=\"https://ttm.financial/S/NS8U.SI\">$HUTCHISON PORT HOLDINGS TRUST(NS8U.SI)$</a>Dividend going XD this week","listText":"Nothing beats the highest yield of HPHT ... 8 TO 9% YEARLY<a href=\"https://ttm.financial/S/NS8U.SI\">$HUTCHISON PORT HOLDINGS TRUST(NS8U.SI)$</a>Dividend going XD this week","text":"Nothing beats the highest yield of HPHT ... 8 TO 9% YEARLY$HUTCHISON PORT HOLDINGS TRUST(NS8U.SI)$Dividend going XD this week","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095061733","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9095015282,"gmtCreate":1644768593458,"gmtModify":1676533959943,"author":{"id":"3581842076108699","authorId":"3581842076108699","name":"小小只样","avatar":"https://static.tigerbbs.com/c7f90d0dc72cf5dbd2ac5c13542c4c87","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581842076108699","authorIdStr":"3581842076108699"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9095015282","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092776098,"gmtCreate":1644751005148,"gmtModify":1676533958832,"author":{"id":"3586301355400538","authorId":"3586301355400538","name":"Edwardtoh","avatar":"https://static.tigerbbs.com/b46042c9b9b5dcea7d55f33bccb139cc","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3586301355400538","authorIdStr":"3586301355400538"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092776098","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092747756,"gmtCreate":1644748536821,"gmtModify":1676533958647,"author":{"id":"4103546058868860","authorId":"4103546058868860","name":"Aninpooh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4103546058868860","authorIdStr":"4103546058868860"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092747756","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092721723,"gmtCreate":1644735642146,"gmtModify":1676533958049,"author":{"id":"3583029437333652","authorId":"3583029437333652","name":"Huntsilencer","avatar":"https://static.tigerbbs.com/9b69d6b5db7ba7ec92be9ac8c5c5705c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583029437333652","authorIdStr":"3583029437333652"},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092721723","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092486952,"gmtCreate":1644713891200,"gmtModify":1676533954681,"author":{"id":"3587008457873110","authorId":"3587008457873110","name":"tig2021","avatar":"https://static.tigerbbs.com/86558e2c1be0fae967630b306994ef5a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3587008457873110","authorIdStr":"3587008457873110"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092486952","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092433866,"gmtCreate":1644710056713,"gmtModify":1676533954037,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092433866","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092494412,"gmtCreate":1644709484576,"gmtModify":1676533953962,"author":{"id":"3575125836760247","authorId":"3575125836760247","name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575125836760247","authorIdStr":"3575125836760247"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092494412","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092575526,"gmtCreate":1644700642461,"gmtModify":1676533953151,"author":{"id":"4096119408780510","authorId":"4096119408780510","name":"Jehms","avatar":"https://static.tigerbbs.com/84c64b2b7d36baf53d2d5bd1dce11972","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"4096119408780510","authorIdStr":"4096119408780510"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092575526","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092544752,"gmtCreate":1644685121511,"gmtModify":1676533952944,"author":{"id":"3586474193512687","authorId":"3586474193512687","name":"Aaronboy","avatar":"https://static.tigerbbs.com/875e45a6d6b604dfaa34ac175ccbbb29","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586474193512687","authorIdStr":"3586474193512687"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092544752","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092558288,"gmtCreate":1644678793538,"gmtModify":1676533952608,"author":{"id":"3582006183410147","authorId":"3582006183410147","name":"DZL","avatar":"https://static.tigerbbs.com/640ac3ae648fded99146300a53c24a5b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582006183410147","authorIdStr":"3582006183410147"},"htmlText":"Gilead Sciences, 3M, buy the dip&nbsp;for long term dividend gain","listText":"Gilead Sciences, 3M, buy the dip&nbsp;for long term dividend gain","text":"Gilead Sciences, 3M, buy the dip for long term dividend gain","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092558288","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092519376,"gmtCreate":1644660539642,"gmtModify":1676533951412,"author":{"id":"4087361572396550","authorId":"4087361572396550","name":"ValuInvestor","avatar":"https://static.tigerbbs.com/5a962911d3cd0763a9f0cb01392cacd9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087361572396550","authorIdStr":"4087361572396550"},"htmlText":"Until <a href=\"https://ttm.financial/S/MMM\">$3M(MMM)$</a>starts showing signs of better business execution, I don't see how it is a good buy","listText":"Until <a href=\"https://ttm.financial/S/MMM\">$3M(MMM)$</a>starts showing signs of better business execution, I don't see how it is a good buy","text":"Until $3M(MMM)$starts showing signs of better business execution, I don't see how it is a good buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092519376","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092597837,"gmtCreate":1644653699967,"gmtModify":1676533951130,"author":{"id":"4107641677984740","authorId":"4107641677984740","name":"tina go","avatar":"https://community-static.tradeup.com/news/60c0446feb328818aaf8cd74f9306156","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4107641677984740","authorIdStr":"4107641677984740"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092597837","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092597087,"gmtCreate":1644653481793,"gmtModify":1676533951125,"author":{"id":"4107641677984740","authorId":"4107641677984740","name":"tina go","avatar":"https://community-static.tradeup.com/news/60c0446feb328818aaf8cd74f9306156","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"4107641677984740","authorIdStr":"4107641677984740"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092597087","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":631636306,"gmtCreate":1644634288184,"gmtModify":1676532710076,"author":{"id":"3581673258710248","authorId":"3581673258710248","name":"Jawslea","avatar":"https://static.tigerbbs.com/8333191726f8892d8ed5ce88d0ca4b94","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3581673258710248","authorIdStr":"3581673258710248"},"htmlText":"Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM)","listText":"Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM)","text":"Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/631636306","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9092283012,"gmtCreate":1644633058250,"gmtModify":1676533949085,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574906731000207","authorIdStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092283012","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9092219035,"gmtCreate":1644631959384,"gmtModify":1676533948595,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Us dividend stocks are.low yield and subjected to taxes....","listText":"Us dividend stocks are.low yield and subjected to taxes....","text":"Us dividend stocks are.low yield and subjected to taxes....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092219035","repostId":2210159258,"repostType":4,"repost":{"id":"2210159258","pubTimestamp":1644592522,"share":"https://ttm.financial/m/news/2210159258?lang=&edition=fundamental","pubTime":"2022-02-11 23:15","market":"us","language":"en","title":"2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2210159258","media":"Motley Fool","summary":"Both offer yields more than twice what the S&P 500 provides.","content":"<html><head></head><body><p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.</p><p>A couple of already high-yielding stocks that are paying more than the <b>S&amp;P 500</b> average of 1.3% and have fallen near their 52-week lows are <b>Gilead Sciences</b> (NASDAQ:GILD) and <b><a href=\"https://laohu8.com/S/MMM\">3M</a></b> (NYSE:MMM). Here&#39;s why despite recent investor bearishness, these could be solid additions to your portfolios today.</p><h2>1. Gilead Sciences</h2><p>Drugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead&#39;s performance for the past three months of 2021 was underwhelming with the company&#39;s sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving <b>Arcus Biosciences</b>.</p><p>For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.</p><p>Even if there is a decline in profitability, those numbers will still be strong enough to support the company&#39;s dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead&#39;s payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.</p><p>Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.</p><p>Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/31d1231300ed8387737ca89664e91e9e\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"/><span>GILD PE Ratio (Forward) data by YCharts.</span></p><h2>2. 3M</h2><p>Multinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic&#39;s early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.</p><p>The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020&#39;s fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.</p><p>Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter&#39;s sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.</p><p>For income investors, the company&#39;s payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there&#39;s little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there&#39;s plenty of room for the company to continue making and increasing payouts.</p><p>3M shares haven&#39;t been this low since the fall of 2020, and the stock&#39;s yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-11 23:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4206":"工业集团企业","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4512":"苹果概念","MMM":"3M","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","GILD":"吉利德科学"},"source_url":"https://www.fool.com/investing/2022/02/10/2-high-yield-dividend-stocks-that-are-trading-near/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210159258","content_text":"When dividend stocks go on sale, it can be an opportunity for investors to lock in a higher-than-normal yield. The dividend yield, of course is a function of both quarterly payments and the share price; when the latter falls, the yield goes up.A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ:GILD) and 3M (NYSE:MMM). Here's why despite recent investor bearishness, these could be solid additions to your portfolios today.1. Gilead SciencesDrugmaker Gilead Sciences is trading at around $63 a share and has been inching closer to its 52-week low of $61.39. The stock nosedived after the company released its latest quarterly results on Feb. 1. Gilead's performance for the past three months of 2021 was underwhelming with the company's sales of $7.2 billion declining 2.4% from the same period a year ago. Net income of $376 million was also just a fraction of the $1.5 billion that it reported a year earlier; the healthcare company says the decline was largely due to a legal settlement of $625 million involving Arcus Biosciences.For 2022, Gilead projects that its sales will come in between $23.8 billion and $24.3 billion; at the midpoint of $24 billion, that would be a decline of 12% from the $27.3 billion it recorded in 2021. The company expects diluted earnings per share (EPS) to be between $4.70 and $5.20 for the year, so it could still potentially come in better than the $4.93-per-share profit it reported this past year.Even if there is a decline in profitability, those numbers will still be strong enough to support the company's dividend, which currently pays shareholders $2.92 per share a year. At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%.Although Gilead is facing some challenges, particularly from losses in exclusivity for some of its key products, the company is working on building out its pipeline. In oncology alone, there are over 30 clinical trials currently taking place.Gilead remains in solid shape despite some risks, and investors are compensated for it as the stock trades at a lower forward price-to-earnings multiple than other drugmakers:GILD PE Ratio (Forward) data by YCharts.2. 3MMultinational conglomerate 3M hit a new 52-week low this week as it also fell out of favor with investors. The company, which makes healthcare masks and respirators, was a popular investment during the pandemic's early stages. And as COVID-19 case numbers began to subside last year and hopes about a return to normal rose, interest in the stock began to wane.The company released fourth-quarter numbers on Jan. 25, reporting sales of $8.6 billion for the period ended Dec. 31, 2021. That was flat from the prior year. Meanwhile, net income declined by 4.7% to $1.3 billion. By contrast, sales rose 5.8% in 2020's fourth quarter. That was largely due to an increase in safety and industrial revenue (including personal hygiene products and masks). This time around, however, that segment of its business fell 2% to about $3.1 billion.Other business units (healthcare, transportation and electronics) are smaller and also showed little or no growth. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers. All this diversification makes the business resilient -- and as a whole, 3M continues to do well. For all of 2021, net sales rose 10% year over year to $35.4 billion.For income investors, the company's payouts look more than safe even if the growth rate starts to falter. 3M is a Dividend King thanks to increasing its dividend payments for more than 60 years in a row. And there's little doubt that streak will continue; it paid out $5.92 per share in dividends for 2021. With an EPS of $10.12, that puts its payout ratio at just 58%. So there's plenty of room for the company to continue making and increasing payouts.3M shares haven't been this low since the fall of 2020, and the stock's yield is currently at 3.7%. Now could be a great time to add this investment to your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1247,"commentSize":306,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}